The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A

Xenobiotica

Volumn 42, Issue 6, 2012, Pages 571-579

  Hanusova V ^a   Bousova I ^a   Pakostova A ^a   Skalova L ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

CBR1; doxorubicin deactivation; doxorubicin hepatotoxicity; non tumourous cell line

Indexed keywords

CARBONYL REDUCTASE; DOXORUBICIN; MENADIONE; ORACIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ALCOHOL OXIDOREDUCTASES; ANIMALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSOL; DOXORUBICIN; DRUG INTERACTIONS; EPITHELIAL CELLS; ETHANOLAMINES; FEMALE; HEPATOCYTES; HUMANS; ISOQUINOLINES; LIVER; RATS; RATS, WISTAR;

RATTUS;

EID: 84860574627     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.645517     Document Type: Article

References (35)

1. Adamcová M, Gersl V, Hrdina R, Melka M, Mazurová Y, Vávrová J, Palicka V, Kokstein Z. (1999). Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 125:268-274.
2. Ax W, Soldan M, Koch L, Maser E. (2000). Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59:293-300.
3. Bae JY, Ahn SJ, Han W, Noh DY. (2007). Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 101:1038-1045.
4. Barnabé N, Marusak RA, Hasinoff BB. (2003). Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide 9:211-216.
5. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-2795.
6. Berry MN, Edwards AM, Barritt GJ. (1991). Isolatedhepatocytespreparation, properties and applications. Laboratorytechniques in biochemistry and molecularbiology. Amsterdam: Elsevier Science.
7. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267-3285.
8. Davies KJA, Doroshow JH. (1986). Radox cycling of anthracyclines by cardiac mitochondria. The Journal of biological chemistry 7: 3060-3067.
9. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. (1996). MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148:313-319.
10. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5:78.
11. Durak I, Canbolat O, Kaçmaz M, Ozgen G, Oztürk HS. (1998). Antioxidant interferences in superoxide dismutase activity methods using superoxide radical as substrate. Clin Chem Lab Med 36:407-408.
12. Erenpreisa J, Cragg MS. (2001). Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1.
13. Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J et al. (2007). 25-Hydroxyvitamin D3 1α-hydroxylase splice variants in breast cell lines between MCF-7 and MCF-10. Cancer Genomics Proteomics 4:295-300.
14. Gajewski E, Gaur S, Akman SA, Matsumoto L, Van Balgooy JN, Doroshow JH. (2007). Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem Pharmacol 73:1947-1956.
15. Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176:9-18.
16. Gersl V, Mazurová Y, Bajgar J, Melka M, Hrdina R, Palicka V. (1996). Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch Toxicol 70:645-651.
17. Hanuŝová V, Bouŝová I, Skálová L. (2011). Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev 43:540-557.
18. Hanusová V, Králová V, Schröterová L, Trilecová L, Pakostová A, Skálová L. (2010). The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF-7 cells. Xenobiotica 40:681-690.
19. Kalender S, Kalender Y, Ates A, Yel M, Olcay E, Candan S. (2002). Protective role of antioxidant vitamin E and catechin on idarubicininduced cardiotoxicity in rats. Braz J Med Biol Res 35:1379-1387.
20. Kalender Y, Yel M, Kalender S. (2005). Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 209:39-45.
21. Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113-2120.
22. Klucar J, Al-Rubeai M. (1997). G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. FEBS Lett 400:127-130.
23. Lewis MJ, Wiebe JP, Heathcote JG. (2004). Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4:27.
24. Lopez de Cerain A, Marin A, Idoate MA, Tunon MT, Bello J. (1999). Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35:320-324.
25. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular adVances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
26. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989-998.
27. Ng R, Better N, Green MD. (2006). Anticancer agents and cardiotoxicity. Semin Oncol 33:2-14.
28. O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with adVanced cancer. Cancer Chemother Pharmacol 59:79-87.
29. Oppermann U. (2007). Carbonyl reductases, the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322.
30. Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181-191.
31. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. (2008). Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 10:35-46.
32. Simunek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171.
33. Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E. (2009). Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology 264:52-60.
34. Trédan O, Galmarini CM, Patel K, Tannock IF. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441-1454.
35. Václavíková R, Kondrová E, Ehrlichová M, Boumendjel A, Kovár J, Stopka P, Soucek P, Gut I. (2008). The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 16:2034-2042.